New approaches to target cancer stem cells: Current scenario

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 1, 2014, Pages 20-34

  Insan, Mayank Bashyal ^a   Jaitak, Vikas ^a  

^a CENTRAL UNIVERSITY OF PUNJAB   (India)

Author keywords

Cancer stem cell; Chemotherapy; CSCs niche; Hedgehog; MicroRNA; Multi targeted anti CSC therapy; Notch; Radiotherapy; Wnt

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CELL MARKER; CURCUMIN; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELL ADHESION MOLECULE; FISETIN; GROWTH HORMONE; HERMES ANTIGEN; LEPTIN; MEPACRINE; MICRORNA; NERVE CELL ADHESION MOLECULE L1; NOTCH1 RECEPTOR; PROLACTIN; RESVERATROL; RETINOIC ACID; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; SONIDEGIB; SULINDAC; TELOMERASE; THY 1 ANTIGEN; UNINDEXED DRUG; VANTICTUMAB; VISMODEGIB; WNT PROTEIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL THERAPY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; HUMAN; HUMAN CELL; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; HUMANS; MICRORNAS; MOLECULAR STRUCTURE; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84896732141     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575113136660107     Document Type: Review

References (128)

1. Klonisch, T.; Wiechec, E.; Hombach-Klonisch, S.; Ande, S. R.; Wesselborg, S.; Schulze-Osthoff, K.; Los, M. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol. Med., 2008, 14(10), 450-460.
2. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 2010, 29(34), 4741-4751.
3. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284.
4. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M. A.; Dick, J. E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 1994, 367(6464), 645-648.
5. Al-Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. P. Natl. Acad. Sci. USA, 2003, 100(7), 3983-3988.
6. Singh, S. K.; Clarke, I. D.; Terasaki, M.; Bonn, V. E.; Hawkins, C.; Squire, J.; Dirks, P. B. Identification of a cancer stem cell in human brain tumors. Cancer Res., 2003, 63(18), 5821-5828.
7. Hirschmann-Jax, C.; Foster, A.; Wulf, G.; Nuchtern, J.; Jax, T.; Gobel, U.; Goodell, M.; Brenner, M. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. P. Natl. Acad. Sci. USA, 2004, 101(39), 14228-14233.
8. Ho, M. M.; Ng, A. V.; Lam, S.; Hung, J. Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res., 2007, 67(10), 4827-4833.
9. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444(7120), 756-760.
10. Sampieri, K.; Fodde, R. In: Cancer stem cells and metastasis, Seminars in Cancer Biology, Elsevier: 2012; pp 187-193.
11. Piotrowicz, R. S.; Damaj, B. B.; Hachicha, M.; Incardona, F.; Howell, S. B.; Finlayson, M. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol. Cancer Ther., 2011, 10(11), 2072-2082.
12. Li, S.-D.; Howell, S. B. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol. Pharm., 2009, 7(1), 280-290.
13. Hassan, H. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leukemia Res., 2009, 33(1), 5-10.
14. Landen, C. N.; Goodman, B.; Katre, A. A.; Steg, A. D.; Nick, A. M.; Stone, R. L.; Miller, L. D.; Mejia, P. V.; Jennings, N. B.; Gershenson, D. M. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther., 2010, 9(12), 3186-3199.
15. Bonnet, D.; Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 1997, 3(7), 730-737.
16. Ginestier, C.; Hur, M. H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C. G.; Liu, S. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 2007, 1(5), 555-567.
17. Wright, M. H.; Calcagno, A. M.; Salcido, C. D.; Carlson, M. D.; Ambudkar, S. V.; Varticovski, L. Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res., 2008, 10(1), R10.
18. Hwang-Verslues, W. W.; Kuo, W.-H.; Chang, P.-H.; Pan, C.-C.; Wang, H.-H.; Tsai, S.-T.; Jeng, Y.-M.; Shew, J.-Y.; Kung, J. T.; Chen, C.-H. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One, 2009, 4(12), e8377.
19. Pece, S.; Tosoni, D.; Confalonieri, S.; Mazzarol, G.; Vecchi, M.; Ronzoni, S.; Bernard, L.; Viale, G.; Pelicci, P. G.; Di Fiore, P. P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell, 2010, 140(1), 62-73.
20. Ma, S.; Chan, K. W.; Hu, L.; Lee, T. K. W.; Wo, J. Y. H.; Ng, I. O. L.; Zheng, B. J.; Guan, X. Y. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 2007, 132(7), 2542-2556.
21. Yang, Z. F.; Ho, D. W.; Ng, M. N.; Lau, C. K.; Yu, W. C.; Ngai, P.; Chu, P. W.; Lam, C. T.; Poon, R. T.; Fan, S. T. Significance of CD90+ Cancer Stem Cells in Human Liver Cancer. Cancer Cell, 2008, 13(2), 153-166.
22. Terris, B.; Cavard, C.; Perret, C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J. Hepatol., 2010, 52(2), 280-281.
23. Haraguchi, N.; Ishii, H.; Mimori, K.; Tanaka, F.; Ohkuma, M.; Kim, H. M.; Akita, H.; Takiuchi, D.; Hatano, H.; Nagano, H. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest., 2010, 120(9), 3326-3339.
24. Zhu, Z.; Hao, X.; Yan, M.; Yao, M.; Ge, C.; Gu, J.; Li, J. Cancer stem/progenitor cells are highly enriched in CD133+ CD44+ population in hepatocellular carcinoma. Int. J. Cancer, 2010, 126(9), 2067-2078.
25. Lee, T. K. W.; Castilho, A.; Cheung, V. C. H.; Tang, K. H.; Ma, S.; Ng, I. O. L. CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation. Cell Stem Cell, 2011, 9(1), 50-63.
26. Yang, W.; Yan, H.-X.; Chen, L.; Liu, Q.; He, Y.-Q.; Yu, L.-X.; Zhang, S.-H.; Huang, D.-D.; Tang, L.; Kong, X.-N. Wnt/catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res., 2008, 68(11), 4287-4295.
27. Cheung, P. F. Y.; Cheng, C. K. C.; Wong, N. C. L.; Ho, J. C. Y.; Yip, C. W.; Lui, V. C. H.; Cheung, A. N. Y.; Fan, S. T.; Cheung, S. T. Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells. PloS One, 2011, 6(12), e28246.
28. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D.; Dirks, P. B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
29. Son, M. J.; Woolard, K.; Nam, D.-H.; Lee, J.; Fine, H. A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell, 2009, 4(5), 440-452.
30. De Bacco, F.; Casanova, E.; Medico, E.; Pellegatta, S.; Orzan, F.; Albano, R.; Luraghi, P.; Reato, G.; D'Ambrosio, A.; Porrati, P. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res., 2012, 72(17), 4537-4550.
31. Li, C.; Heidt, D. G.; Dalerba, P.; Burant, C. F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M. F.; Simeone, D. M. Identification of pancreatic cancer stem cells. Cancer Res., 2007, 67(3), 1030-1037.
32. Hermann, P. C.; Huber, S. L.; Herrler, T.; Aicher, A.; Ellwart, J. W.; Guba, M.; Bruns, C. J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007, 1(3), 313-323.
33. Li, C.; Wu, J. J.; Hynes, M.; Dosch, J.; Sarkar, B.; Welling, T. H.; Pasca di Magliano, M.; Simeone, D. M. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology, 2011, 141(6), 2218-2227. e5.
34. Kim, M. P.; Fleming, J. B.; Wang, H.; Abbruzzese, J. L.; Choi, W.; Kopetz, S.; McConkey, D. J.; Evans, D. B.; Gallick, G. E. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One, 2011, 6(6), e20636.
35. Collins, A. T.; Berry, P. A.; Hyde, C.; Stower, M. J.; Maitland, N. J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res., 2005, 65(23), 10946-10951.
36. Miki, J.; Furusato, B.; Li, H.; Gu, Y.; Takahashi, H.; Egawa, S.; Sesterhenn, I. A.; McLeod, D. G.; Srivastava, S.; Rhim, J. S. Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERT-Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer Specimens. Cancer Res., 2007, 67(7), 3153-3161.
37. Chauchereau, A.; Al Nakouzi, N.; Gaudin, C.; Le Moulec, S.; Compagno, D.; Auger, N.; Bénard, J.; Opolon, P.; Rozet, F.; Validire, P. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp. Cell Res., 2011, 317(3), 262-275.
38. Prince, M.; Sivanandan, R.; Kaczorowski, A.; Wolf, G.; Kaplan, M.; Dalerba, P.; Weissman, I.; Clarke, M.; Ailles, L. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. P. Natl. Acad. Sci. USA, 2007, 104(3), 973-978.
39. Clay, M. R.; Tabor, M.; Owen, J. H.; Carey, T. E.; Bradford, C. R.; Wolf, G. T.; Wicha, M. S.; Prince, M. E. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head & Neck, 2010, 32(9), 1195-1201.
40. Takebe, N.; Harris, P. J.; Warren, R. Q.; Ivy, S. P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol., 2010, 8(2), 97-106.
41. Kar, S.; Deb, M.; Sengupta, D.; Shilpi, A.; Bhutia, S. K.; Patra, S. K. Intricacies of hedgehog signaling pathways: a perspective in tumorigenesis. Exp. Cell. Res., 2012, 318(16), 1959-1972.
42. Yanai, K.; Nakamura, M.; Akiyoshi, T.; Nagai, S.; Wada, J.; Koga, K.; Noshiro, H.; Nagai, E.; Tsuneyoshi, M.; Tanaka, M. Crosstalk of hedgehog and Wnt pathways in gastric cancer. Cancer Lett., 2008, 263(1), 145-156.
43. Palacios, J.; Gamallo, C. Mutations in the catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res., 1998, 58(7), 1344-1347.
44. Yokota, N.; Nishizawa, S.; Ohta, S.; Sugimura, H.; Namba, H.; Maekawa, M. Role of Wnt pathway in medulloblastoma oncogenesis. Int. J. Cancer, 2002, 101(2), 198-201.
45. Fan, X.; Matsui, W.; Khaki, L.; Stearns, D.; Chun, J.; Li, Y.-M.; Eberhart, C. G. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res., 2006, 66(15), 7445-7452.
46. Westhoff, B.; Colaluca, I. N.; D'Ario, G.; Donzelli, M.; Tosoni, D.; Volorio, S.; Pelosi, G.; Spaggiari, L.; Mazzarol, G.; Viale, G. Alterations of the Notch pathway in lung cancer. P. Natl. Acad. Sci. USA, 2009, 106(52), 22293-22298.
47. Dontu, G.; Abdallah, W. M.; Foley, J. M.; Jackson, K. W.; Clarke, M. F.; Kawamura, M. J.; Wicha, M. S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Gene Dev., 2003, 17(10), 1253-1270.
48. Kritikou, E. A.; Sharkey, A.; Abell, K.; Came, P. J.; Anderson, E.; Clarkson, R. W.; Watson, C. J. A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development, 2003, 130(15), 3459-3468.
49. Salam, K.; Aydur, E.; Yilmaz, M. I.; Goktas, S. Leptin Influences Cellular Differentiation And Progression In Prostrate Cancer. J. Urology., 2003, 169(4), 1308-1311.
50. Ju, Z.; Rudolph, K. L. Telomeres and telomerase in cancer stem cells. Eur. J. Cancer, 2006, 42(9), 1197-1203.
51. Savarese, T. M.; Strohsnitter, W. C.; Low, H. P.; Liu, Q.; Baik, I.; Okulicz, W.; Chelmow, D. P.; Lagiou, P.; Quesenberry, P. J.; Noller, K. L. Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis. Breast Cancer Res., 2007, 9(3), R29.
52. Garvalov, B. K.; Acker, T. Cancer stem cells: a new framework for the design of tumor therapies. J. Mol. Med., 2011, 89(2), 95-107.
53. Jin, L.; Hope, K. J.; Zhai, Q.; Smadja-Joffe, F.; Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med., 2006, 12(10), 1167-1174.
54. Deonarain, M. P.; Kousparou, C. A.; Epenetos, A. A. In Antibodies targeting cancer stem cells: A new paradigm in immunotherapy?, MAbs, Landes Bioscience: 2009; pp 12-25.
55. Herrmann, H.; Cerny-Reiterer, S.; Gleixner, K. V.; Blatt, K.; Herndlhofer, S.; Rabitsch, W.; Jäger, E.; Mitterbauer-Hohendanner, G.; Streubel, B.; Selzer, E. CD34+/CD38 stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica, 2012, 97(2), 219-226.
56. Salnikov, A. V.; Groth, A.; Apel, A.; Kallifatidis, G.; Beckermann, B. M.; Khamidjanov, A.; Ryschich, E.; Büchler, M. W.; Herr, I.; Moldenhauer, G. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J. Cell. Mol. Med., 2009, 13(9b), 4023-4033.
57. Ohlfest, J. R.; Zellmer, D. M.; Panyam, J.; Swaminathan, S. K.; Oh, S.; Waldron, N. N.; Toma, S.; Vallera, D. A. Immunotoxin targeting CD133+ breast carcinoma cells. Drug Deliv. Transl. Res., 2012, 3(2), 195-204.
58. Lee, T. K. W.; Cheung, V. C. H.; Ng, I. O. L. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett., 2012, 338(1), 101-109.
59. Wang, C. H.; Chiou, S. H.; Chou, C. P.; Chen, Y. C.; Huang, Y. J.; Peng, C. A. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomed-Nanotechnol., 2011, 7(1), 69-79.
60. Bao, S.; Wu, Q.; Li, Z.; Sathornsumetee, S.; Wang, H.; McLendon, R. E.; Hjelmeland, A. B.; Rich, J. N. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res., 2008, 68(15), 6043-6048.
61. Calvi, L.; Adams, G.; Weibrecht, K.; Weber, J.; Olson, D.; Knight, M.; Martin, R.; Schipani, E.; Divieti, P.; Bringhurst, F. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature, 2003, 425(6960), 841-846.
62. Kiel, M. J.; Morrison, S. J. Maintaining hematopoietic stem cells in the vascular niche. Immunity, 2006, 25(6), 862-864.
63. Iwasaki, H.; Suda, T., Cancer stem cells and their niche. Cancer Sci., 2009, 100(7), 1166-1172.
64. Krause, D. S.; Lazarides, K.; von Andrian, U. H.; Van Etten, R. A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med., 2006, 12(10), 1175-1180.
65. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T. L.; Fuller, C.; Hamner, B.; Oh, E. Y.; Gaber, M. W.; Finklestein, D.; Allen, M. A perivascular niche for brain tumor stem cells. Cancer Cell, 2007, 11(1), 69-82.
66. Willett, C. G.; Boucher, Y.; di Tomaso, E.; Duda, D. G.; Munn, L. L.; Tong, R T.; Chung, D. C.; Sahani, D. V.; Kalva, S. P.; Kozin, S. V. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 2004, 10(2), 145-147.
67. Seidel, S.; Garvalov, B. K.; Wirta, V.; von Stechow, L.; Schänzer, A.; Meletis, K.; Wolter, M.; Sommerlad, D.; Henze, A.-T.; Nistér, M. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2. Brain, 2010, 133(4), 983-995.
68. Bokesch, H. R.; Gardella, R. S.; Daniel Christopher, R.; Bottaro, D. P.; Linehan, W. M.; McMahon, J. B.; McKee, T. C. A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. Chem. Pharm. Bull., 2011, 59(9), 1178.
69. Evangelista, M.; Tian, H.; de Sauvage, F. J. The hedgehog signaling pathway in cancer. Clin. Cancer Res., 2006, 12(9), 5924-5928.
70. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414(6859), 105-111.
71. Johnson, R. L.; Rothman, A. L.; Xie, J.; Goodrich, L. V.; Bare, J. W.; Bonifas, J. M.; Quinn, A. G.; Myers, R. M.; Cox, D. R.; Epstein, E. H. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science, 1996, 272(5268), 1668-1671.
72. Rubin, L. L.; de Sauvage, F. J. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov., 2006, 5(12), 1026-1033.
73. Peukert, S.; Miller-Moslin, K. Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics. Chem. Med. Chem., 2010, 5(4), 500-512.
74. Chen, J. K.; Taipale, J.; Cooper, M. K.; Beachy, P. A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Gene Dev., 2002, 16(21), 2743-2748.
75. Jimeno, A.; Weiss, G. J.; Miller, W. H.; Gettinger, S.; Eigl, B. J.; Chang, A. L. S.; Dunbar, J.; Devens, S.; Faia, K.; Skliris, G. Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. Clin. Cancer Res., 2013, 19(10), 2766-2774.
76. Kasper, M.; Toftgård, R. Smoothing out drug resistance. Cancer Cell, 2013, 23(1), 3-5.
77. Fecher, L. A. Systemic Therapy for Inoperable and Metastatic Basal Cell Cancer. Curr. Treat. Option. Oncol., 2013, 14(2) 237-248.
78. Ohashi, T.; Oguro, Y.; Tanaka, T.; Shiokawa, Z.; Tanaka, Y.; Shibata, S.; Sato, Y.; Yamakawa, H.; Hattori, H.; Yamamoto, Y.; Kondo, S.; Miyamoto, M.; Nishihara, M.; Ishimura, Y.; Tojo, H.; Baba, A.; Sasaki, S. Discovery of the investigational drug TAK-441, a pyrrolo[3, 2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility. Bioorgan. Med. Chem., 2012, 20(18), 5507-5517.
79. Peukert, S.; He, F.; Dai, M.; Zhang, R.; Sun, Y.; Miller-Moslin, K.; McEwan, M.; Lagu, B.; Wang, K.; Yusuff, N.; Bourret, A.; Ramamurthy, A.; Maniara, W.; Amaral, A.; Vattay, A.; Wang, A.; Guo, R.; Yuan, J.; Green, J.; Williams, J.; Buonamici, S.; Kelleher, J. F.; Dorsch, M. Discovery of NVP-LEQ506, a Second-Generation Inhibitor of Smoothened. Chem. Med. Chem., 2013, 8(8), 1261-1265.
80. Nusse, R.; Varmus, H. E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 1982, 31(1), 99-109.
81. Muller, J.-M.; Chevrier, L.; Cochaud, S.; Meunier, A.-C.; Chadeneau, C. Hedgehog, Notch and Wnt developmental pathways as targets for anti-cancer drugs. Drug Discov. Today Dis. Mech., 2008, 4(4), 285-291.
82. Izrailit, J.; Reedijk, M. Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications. Cancer Lett., 2012, 317(2), 115-126.
83. Karamboulas, C.; Ailles, L. Developmental signaling pathways in cancer stem cells of solid tumors. Bba-Gen. Subjects, 2012, 1830(20), 2481-2495.
84. Reya, T.; Clevers, H. Wnt signalling in stem cells and cancer. Nature, 2005, 434(7035), 843-850.
85. Wend, P.; Holland, J. D.; Ziebold, U.; Birchmeier, W. In Wnt signaling in stem and cancer stem cells, Seminars in cell & developmental biology, Elsevier: 2010; 21, pp 855-863.
86. Chen, B.; Dodge, M. E.; Tang, W.; Lu, J.; Ma, Z.; Fan, C.-W.; Wei, S.; Hao, W.; Kilgore, J.; Williams, N. S. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol., 2009, 5(2), 100-107.
87. Takahashi-Yanaga, F.; Kahn, M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin. Cancer Res., 2010, 16(12), 3153-3162.
88. Grandy, D.; Shan, J.; Zhang, X.; Rao, S.; Akunuru, S.; Li, H.; Zhang, Y.; Alpatov, I.; Zhang, X. A.; Lang, R. A. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem., 2009, 284 (24), 16256-16263.
89. Eguchi, M.; Nguyen, C.; Lee, S. C.; Kahn, M. ICG-001, A Novel Small Molecule Regulator of TCF/beta-Catenin Masakatsu Transcription. Med. Chem., 2005, 1(5), 467-472.
90. Gurney, A.; Axelrod, F.; Bond, C. J.; Cain, J.; Chartier, C.; Donigan, L.; Fischer, M.; Chaudhari, A.; Ji, M.; Kapoun, A. M. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. P. Natl. Acad. Sci. USA, 2012, 109(29), 11717-11722.
91. Grossmann, T. N.; Yeh, J. T.-H.; Bowman, B. R.; Chu, Q.; Moellering, R. E.; Verdine, G. L. Inhibition of oncogenic Wnt signaling through direct targeting of catenin. P. Natl. Acad. Sci. USA, 2012, 109(44), 17942-17947.
92. Lu, D.; Choi, M. Y.; Yu, J.; Castro, J. E.; Kipps, T. J.; Carson, D. A. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. P. Natl. Acad. Sci. USA, 2011, 108(32), 13253-13257.
93. Stein, U.; Arlt, F.; Smith, J.; Sack, U.; Herrmann, P.; Walther, W.; Lemm, M.; Fichtner, I.; Shoemaker, R. H.; Schlag, P. M. Intervening in catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia, 2011, 13(2), 131-144.
94. Syed, D. N.; Afaq, F.; Maddodi, N.; Johnson, J. J.; Sarfaraz, S.; Ahmad, A.; Setaluri, V.; Mukhtar, H. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/catenin signaling and decreased mitf levels. J. Invest. Dermatol., 2011, 131(6), 1291-1299.
95. He, B.-C.; Gao, J.-L.; Zhang, B.-Q.; Luo, Q.; Shi, Q.; Kim, S. H.; Huang, E.; Gao, Y.; Yang, K.; Wagner, E. R. Tetrandrine inhibits Wnt/catenin signaling and suppresses tumor growth of human colorectal cancer. Mol. Pharmacol., 2011, 79(2), 211-219.
96. Park, S.; Chun, S. Streptonigrin inhibits Catenin/Tcf signaling and shows cytotoxicity in catenin-activated cells. Bba-Gen. Subjects, 2011, 1810(12), 1340-1345.
97. Froeling, F. E.; Feig, C.; Chelala, C.; Dobson, R.; Mein, C. E.; Tuveson, D. A.; Clevers, H.; Hart, I. R.; Kocher, H. M. Retinoic Acid-Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt-Catenin Signaling to Slow Tumor Progression. Gastroenterology, 2011, 141(4), 1486-1497.
98. Preet, R.; Mohapatra, P.; Das, D.; Satapathy, S. R.; Choudhuri, T.; Wyatt, M. D.; Kundu, C. N. Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. Carcinogenesis, 2013, 34(2), 277-286.
99. Wang, M. M. Notch signaling and Notch signaling modifiers. Int. J. Biochem. Cell B., 2011, 43(11), 1550-1562.
100. Bolós, V.; Grego-Bessa, J.; de la Pompa, J. L. Notch signaling in development and cancer. Endocr. Rev., 2007, 28(3), 339-363.
101. Stylianou, S.; Clarke, R. B.; Brennan, K. Aberrant activation of notch signaling in human breast cancer. Cancer Res., 2006, 66(3), 1517-1525.
102. Allenspach, E. J.; Maillard, I.; Aster, J. C.; Pear, W. S. Notch signaling in cancer. Cancer Biol. Ther., 2002, 1(5), 466-476.
103. Bolós, V.; Blanco, M.; Medina, V.; Aparicio, G.; Díaz-Prado, S.; Grande, E. Notch signalling in cancer stem cells. Clin. Transl. Oncol., 2009, 11(1), 11-19.
104. Groth, C.; Fortini, M. E. In Therapeutic approaches to modulating Notch signaling: Current challenges and future prospects, Seminars in cell & developmental biology, Elsevier: 2012; pp 465-472.
105. Espinoza, I.; Miele, L. Notch inhibitors for cancer treatment. Pharmacol. Therapeut., 2013, 139(2), 95-110.
106. Gurney, A.; Hoey, T. Anti-DLL4, a cancer therapeutic with multiple mechanisms of action. Vasc. Cell, 2011, 3(18), 1-4.
107. Zhang, B.; Pan, X.; Cobb, G. P.; Anderson, T. A. microRNAs as oncogenes and tumor suppressors. Dev. Biol., 2007, 302(1), 1-12.
108. Calin, G. A.; Dumitru, C D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. P. Natl. Acad. Sci. USA, 2002, 99(24), 15524-15529.
109. Cimmino, A.; Calin, G. A.; Fabbri, M.; Iorio, M. V.; Ferracin, M.; Shimizu, M.; Wojcik, S. E.; Aqeilan, R. I.; Zupo, S.; Dono, M. miR-15 and miR-16 induce apoptosis by targeting BCL2. P. Natl. Acad. Sci. USA, 2005, 102(39), 13944-13949.
110. Pan, X.; Wang, Z.-X.; Wang, R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther., 2010, 10(12), 1224-1232.
111. Medina, P. P.; Nolde, M.; Slack, F. J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 2010, 467(7311), 86-90.
112. Zhu, S.; Si, M.-L.; Wu, H.; Mo, Y.-Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem., 2007, 282(19), 14328-14336.
113. Hwang-Verslues, W.; Chang, P.; Wei, P.; Yang, C.; Huang, C.; Kuo, W.; Shew, J.; Chang, K.; Lee, E. Y. P.; Lee, W. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of Ecadherin and REDD1. Oncogene, 2011, 30(21), 2463-2474.
114. Meng, F.; Glaser, S. S.; Francis, H.; DeMorrow, S.; Han, Y.; Passarini, J. D.; Stokes, A.; Cleary, J. P.; Liu, X.; Venter, J. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J. Cell. Mol. Med., 2012, 16(1), 160-173.
115. Otsubo, T.; Akiyama, Y.; Hashimoto, Y.; Shimada, S.; Goto, K.; Yuasa, Y. MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One, 2011, 6(1), e16617.
116. Shi, L.; Zhang, J.; Pan, T.; Zhou, J.; Gong, W.; Liu, N.; Fu, Z.; You, Y. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res., 2010, 1312, 120-126.
117. King, C. E.; Cuatrecasas, M.; Castells, A.; Sepulveda, A. R.; Lee, J.-S.; Rustgi, A. K. LIN28B promotes colon cancer progression and metastasis. Cancer Res., 2011, 71(12), 4260-4268.
118. Mott, J. L.; Kobayashi, S.; Bronk, S. F.; Gores, G. J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene, 2007, 26(42), 6133-6140.
119. Shi, L.; Zhang, S.; Feng, K.; Wu, F.; Wan, Y.; Wang, Z.; Zhang, J.; Wang, Y.; Yan, W.; Fu, Z. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int. J. Oncol., 2011, 40(1), 119-129.
120. Bian, S.; Sun, T. Functions of noncoding RNAs in neural development and neurological diseases. Mol. Neurobiol., 2011, 44(3), 359-373.
121. Lo, W. L.; Yu, C. C.; Chiou, G. Y.; Chen, Y. W.; Huang, P. I.; Chien, C. S.; Tseng, L. M.; Chu, P. Y.; Lu, K. H.; Chang, K. W. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J. Pathol., 2011, 223(4), 482-495.
122. Yu, Z.; Pestell, R. G. MicroRNAs and cancer stem cells. In MicroRNAs in cancer translational research, Springer: 2011; pp 373-388.
123. Leal, J.; Lleonart, M. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett., 2012, 338(1), 174-183.
124. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multitarget drugs: the network approach might help drug design. Trends Pharmacol. Sci., 2005, 26(4), 178-182.
125. Shou, J.; Massarweh, S.; Osborne, C. K.; Wakeling, A. E.; Ali, S.; Weiss, H.; Schiff, R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer I., 2004, 96(12), 926-935.
126. Gyurko, D. M.; Veres, D. V.; Modos, D.; Lenti, K.; Korcsmáros, T.; Csermely, P. Adaptation and learning of molecular networks as a description of cancer development at the systems-level: Potential use in anti-cancer therapies. Seminars Cancer Biol., 2013, 23, 262-269.
127. Takebe, N.; Harris, P. J.; Warren, R. Q.; Ivy, S. P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol., 2010, 8(2), 97-106.
128. Csermely, P.; Korcsmáros, T.; Kiss, H. J.; London, G.; Nussinov, R. Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review. Pharmacol. Therapeut., 2013, 138(3), 333-408.